NCT00145431

TerminatedPhase 3

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In ...

Pfizer Source

Pfizer

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

A5091024

Study Type

interventional

Actual enrollment (reported)

41

Locations

2 countries

Sites

27

Timeline

Study Start

March 2005

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2006

Actual (reported)

Study Completion

December 2006

Actual (reported)

Brief Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: terminated
Actual enrollment (reported): 41 participants
Study completion date: December 2006
Actual (reported)
Listed locations: 2 countries · 27 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
March 2005
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
August 31, 2005
Actual (reported)
First Posted
September 5, 2005
Actual (reported)
Primary Completion
December 2006
Actual (reported)
Study Completion
December 2006
Actual (reported)

Last Updated: February 17, 2012
Status Verified: February 2012
Last Update Submitted: February 15, 2012

Conditions

Hyperlipoproteinemia Type III

Outcome Measures

Primary Outcomes (1)

Change in LDL-C and non-HDL-C levels.

Secondary Outcomes (1)

Changes in other lipid and biomarker variable levels.

Interventions

torcetrapib/atorvastatinDrug

atorvastatinDrug

fenofibrateDrug

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Diagnosis of Familial Dysbetalipoproteinemia (Fredrickson Type III hyperlipoproteinemia)

You may not qualify if:

Sponsors & Collaborators

Pfizer
Industrylead

Study Sites (27)

Pfizer Investigational Site

Anaheim, California, 92804, United States

Pfizer Investigational Site

Huntington Beach, California, 92648, United States

Pfizer Investigational Site

Orange, California, 92868, United States

Pfizer Investigational Site

Pacific Palisades, California, 90272, United States

Pfizer Investigational Site

Studio City, California, 91604, United States

Pfizer Investigational Site

Tustin, California, 92780, United States

Pfizer Investigational Site

Hollywood, Florida, 33021, United States

MeSH Terms

Conditions

Hyperlipoproteinemia Type III

Interventions

torcetrapibAtorvastatinFenofibrate

Condition Hierarchy (Ancestors)

Lipid Metabolism, Inborn ErrorsMetabolism, Inborn ErrorsGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHyperlipoproteinemiasHyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

Pfizer CT.gov Call Center
Pfizer
STUDY DIRECTOR

Enrollment

41 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: DOUBLE
Purpose: TREATMENT
Intervention Model: CROSSOVER
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 31, 2005

First Posted

September 5, 2005

Study Start

March 2005

Date type not reported

This date has not been verified as actual or estimated.

Terminated

NCT00137462

Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

Phase 3Completed

NCT00134238

Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.

Phase 3Terminated

NCT00134173

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

Phase 3Completed

NCT00139061

Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate

Phase 3Completed

NCT00134511

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder

Phase 3Completed

NCT00214604

Type III Dysbetalipoproteinemia

Phase 3Completed

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Women who are pregnant or lactating, or planning to become pregnant.

Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid

Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors

Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study

Contact the study team to confirm eligibility.

Pfizer Investigational Site

Longwood, Florida, 32779, United States

Pfizer Investigational Site

Tripler Army Medical Center, Hawaii, 96859-5000, United States

Pfizer Investigational Site

Scarborough, Maine, 04074, United States

Pfizer Investigational Site

Portage, Michigan, 49002, United States

Pfizer Investigational Site

Portage, Michigan, 49024, United States

Pfizer Investigational Site

Olive Branch, Mississippi, 38654, United States

Pfizer Investigational Site

Rochester, New York, 14618, United States

Pfizer Investigational Site

Syracuse, New York, 13210, United States

Pfizer Investigational Site

West Seneca, New York, 14224, United States

Pfizer Investigational Site

Sellersville, Pennsylvania, 18960, United States

Pfizer Investigational Site

Greer, South Carolina, 29651, United States

Pfizer Investigational Site

Memphis, Tennessee, 38105, United States

Pfizer Investigational Site

Salt Lake City, Utah, 84108, United States

Pfizer Investigational Site

Seattle, Washington, 98104, United States

Pfizer Investigational Site

Madison, Wisconsin, 53719, United States

Pfizer Investigational Site

London, Ontario, N6A 5K8, Canada

Pfizer Investigational Site

Chicoutimi, Quebec, G7H 5H6, Canada

Pfizer Investigational Site

Montreal, Quebec, H1T 1C8, Canada

Pfizer Investigational Site

Montreal, Quebec, H2W 1R7, Canada

Pfizer Investigational Site

Québec, Quebec, G1V 4M6, Canada

Intervention Hierarchy (Ancestors)

PyrrolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeptanoic AcidsFatty AcidsLipidsFibric AcidsIsobutyratesButyratesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsPhenyl EthersEthersBenzophenonesBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsPhenolsKetones

Primary Completion

December 2006

Actual (reported)

Study Completion

December 2006

Actual (reported)

Last Updated

February 17, 2012

Record last verified: 2012-02

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00145431
Data provider: ClinicalTrials.gov
Source updated: 2012-02-17
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:29:53 UTC

Locations

CA(5)US(22)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (27)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations